-
公开(公告)号:EP3733191B1
公开(公告)日:2024-07-10
申请号:EP20168785.2
申请日:2016-04-20
IPC分类号: A61K31/635 , A61K38/20 , A61K31/21 , A61P31/18 , A61K45/06
CPC分类号: A61K38/2013 , A61K45/06 , A61K31/21 , A61K31/635 , A61P31/18
-
-
公开(公告)号:EP4277592A1
公开(公告)日:2023-11-22
申请号:EP22739266.9
申请日:2022-01-13
申请人: Liliger Ltd
发明人: RON, Eyal S. , TAMARKIN, Dov , SHEMER, Avner
-
公开(公告)号:EP3945848A1
公开(公告)日:2022-02-09
申请号:EP20767301.3
申请日:2020-03-04
发明人: TRACY, Bryan P. , KARPOL, Alon , EYAL, Aharon M.
-
5.
公开(公告)号:EP3697407A1
公开(公告)日:2020-08-26
申请号:EP18867524.3
申请日:2018-10-16
发明人: MISHRA, Manoj , SHARMA, H., Rajan , PATEL, Deven
IPC分类号: A61K31/21 , A61K31/225 , C07C69/60
-
公开(公告)号:EP3646861A1
公开(公告)日:2020-05-06
申请号:EP18204420.6
申请日:2018-11-05
申请人: Kruse, Marcus , Rassaf, Tienush
发明人: Kruse, Marcus , Rassaf, Tienush
IPC分类号: A61K31/21 , A61K31/522 , A61K36/185 , A61K36/31 , A61P9/12
摘要: Die vorliegende Erfindung betrifft eine Zusammensetzung mit konzentrationsfördernder und/oder anregender Wirkung, insbesondere zur gleichzeitigen Senkung des arteriellen Blutdrucks, wobei die Zusammensetzung als Komponente (a) mindestens eine Nitratquelle und/oder Nitrat und als Komponente (b) mindestens eine Substanz mit stimulierender und/oder anregender Wirkung, vorzugsweise Koffein, enthält.
-
-
公开(公告)号:EP2654455B1
公开(公告)日:2018-10-24
申请号:EP11819164.2
申请日:2011-12-20
申请人: DSM IP Assets B.V.
发明人: DUVAL, Stephane , KINDERMANN, Maik
IPC分类号: A23K20/111 , A23K20/121 , A23K20/10 , A23K20/105 , A23K50/10 , A61K31/04 , A61K31/045 , A61K31/08 , A61K31/18 , A61K31/21 , A61K31/216 , A61K31/22 , A61K31/24 , A61K31/275 , A61K31/34 , A61K31/345 , A61K31/4406 , C07D213/82 , C07D493/04 , C07D307/72
CPC分类号: C07C203/04 , A23K20/10 , A23K20/105 , A23K20/111 , A23K20/121 , A23K50/10 , A61K31/04 , A61K31/045 , A61K31/08 , A61K31/18 , A61K31/21 , A61K31/216 , A61K31/22 , A61K31/24 , A61K31/275 , A61K31/34 , A61K31/345 , A61K31/4406 , A61K45/06 , C07C207/02 , C07C207/04 , C07C255/11 , C07C311/03 , C07C311/24 , C07D213/82 , C07D307/72 , C07D493/04 , Y02P60/56
摘要: The present invention relates to a method for reducing the production of methane emanating from the digestive activities of a ruminant and/or for improving ruminant animal performance by using, as active compound at least one organic molecule substituted at any position with at least one nitrooxy group, or a salt thereof, which is administrated to the animal together with the feed. The invention also relates to the use of these compounds in feed and feed additives such as premix, concentrates and total mixed ration (TMR) or in the form of a bolus.
-
公开(公告)号:EP3383383A1
公开(公告)日:2018-10-10
申请号:EP16809686.5
申请日:2016-12-02
申请人: Nestec S.A.
发明人: CUENOUD, Bernard , MASOODI, Mojgan
CPC分类号: A61K31/21 , A23K20/158 , A23L33/12 , A23V2002/00
摘要: A composition comprising medium-chain triglycerides (MCTs) wherein the composition comprises (i) a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8) and (ii) a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10); wherein the ratio of MCT-C8 to MCT-C10 is from 10:90 to 90:10 (mol/mol) and wherein the combined amount of MCT-C8 and MCT-C10 make up at least 50 mol % of the MCTs in the composition.
-
10.
公开(公告)号:EP3195168A4
公开(公告)日:2018-07-25
申请号:EP15827186
申请日:2015-07-31
IPC分类号: G06F19/12 , A61K31/203 , A61K31/21 , A61K31/34 , A61K31/382 , A61K31/4415 , A61K31/445 , A61K38/17 , A61K39/39 , A61K45/06 , C07K16/28 , G06F19/18
CPC分类号: C07K16/2818 , A61K31/198 , A61K31/203 , A61K31/21 , A61K31/216 , A61K31/34 , A61K31/382 , A61K31/409 , A61K31/4415 , A61K31/445 , A61K31/4468 , A61K31/453 , A61K31/495 , A61K31/506 , A61K31/55 , A61K31/551 , A61K31/58 , A61K38/1793 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/55 , C07K16/2878 , C07K2317/76 , G06F19/12 , G06F19/18 , A61K2300/00
摘要: This invention relates to systems and methods for evaluating the differentiality of a set of discrete random variables between two or more conditions, such as a malignant condition responding to treatment regime and one that is not. It also provides for the identification and selection of drugs that act in coordinated manner to phenocopy a genetic network of a malignant condition that responds to at least an immune checkpoint blockade agent.
-
-
-
-
-
-
-
-
-